How much does semaglutide reduce hsCRP, and does that matter for your health?

What hsCRP actually measures, and why the number matters

C-reactive protein is produced by the liver in response to inflammation anywhere in the body. The high-sensitivity version of the test detects even low concentrations, levels that sit below what a standard CRP test would flag, but that still predict meaningful cardiovascular risk over time. Cardiologists have used hsCRP as a risk marker for decades because it adds information that cholesterol panels alone can miss. A reading consistently above 3 mg/L is considered high-risk; below 1 mg/L is low-risk. Many people living with obesity sit in the elevated range without knowing it, because visceral fat is metabolically active tissue that quietly drives inflammation.

This is the context that makes semaglutide's effect on hsCRP worth discussing. Weight loss of almost any kind tends to lower inflammation, so some hsCRP reduction was always expected. The question the trials tried to answer is whether semaglutide produces a reduction proportionate to the weight lost, or something more.

If you've been told your hsCRP is elevated and you're trying to work out what to do about it, that question probably feels quite pressing. The honest answer is that the science is still developing, but what's available is genuinely encouraging.

What the trial data shows about semaglutide and hsCRP reduction

The STEP 1 trial, published in the New England Journal of Medicine, randomised over 1,900 adults with obesity to weekly semaglutide 2.4 mg or placebo over 68 weeks, alongside lifestyle support. Average body weight fell by around 15% in the semaglutide group. hsCRP was measured as a secondary endpoint, and the reductions were striking: if you want to understand exactly how large those reductions were, our page covering the semaglutide hsCRP reduction percentage breaks down the figures from the key trials in full. That gap is not easily explained by weight loss alone, because the placebo group also lost some weight without seeing comparable hsCRP changes.

The SELECT trial, which enrolled over 17,000 adults with established cardiovascular disease and obesity but without diabetes, found a significant reduction in major cardiovascular events with semaglutide. Reductions in inflammatory markers including hsCRP were noted alongside the cardiovascular benefit, you can read a full breakdown of those cardiovascular outcomes on the SELECT trial results page. That finding matters because it raises the possibility that inflammation reduction is part of the mechanism through which semaglutide protects the heart, not merely a side-effect of losing weight.

It is also worth noting that semaglutide affects visceral fat disproportionately, the fat stored around internal organs rather than just beneath the skin. Visceral fat is the main inflammatory driver, so its preferential reduction may partly explain why hsCRP falls as much as it does. There is a fuller account of semaglutide's effect on visceral fat in the semaglutide visceral fat reduction evidence summary if you want to read the two findings side by side.

Does the hsCRP benefit go beyond weight loss?

This is the question researchers are genuinely debating. One approach is to look at studies that adjust for the amount of weight lost and ask whether hsCRP still falls more in the semaglutide group than the adjustment would predict. Several analyses suggest the answer is yes, that there may be a direct anti-inflammatory effect of GLP-1 receptor agonism that operates independently of fat mass reduction. GLP-1 receptors are expressed on immune cells including macrophages, and laboratory studies have shown semaglutide can reduce the production of pro-inflammatory cytokines directly.

That said, separating drug effect from weight-loss effect in a clinical trial is methodologically difficult, and the honest position is that the relative contributions are not yet precisely quantified. What can be said with confidence is that, in people who take semaglutide and lose weight, hsCRP tends to fall substantially, and that this fall is associated with the cardiovascular outcomes seen in SELECT. For a broader look at how semaglutide performs across its weight-loss endpoints, the Wegovy weight loss percentage page covers the headline figures in detail.

The NHS guidance on semaglutide provides a reliable summary of the medicine's established effects and side-effect profile, and the NHS semaglutide page is worth bookmarking alongside any research you do. If you are also curious whether semaglutide carries any vascular risk of its own, the Wegovy and blood clots explainer addresses that question directly.

How this fits into the decision about whether semaglutide is right for you

hsCRP is not a standalone reason to start or avoid semaglutide. It is one piece of a broader clinical picture that a prescriber will consider: your BMI, your weight-related conditions, your cardiovascular history, other medicines you take, and your own priorities. The inflammation data is part of why the cardiovascular evidence for semaglutide is as strong as it is, and for someone whose elevated hsCRP sits alongside obesity and cardiovascular risk factors, that evidence base matters.

Semaglutide (Wegovy) is a prescription-only medicine. No online tool or article can tell you whether it is appropriate for your situation; that assessment has to come from a prescriber who reviews your full picture. Equally, cost is a practical factor, and it is worth reading an honest account of what Wegovy costs in the UK before making a decision. If you'd like to explore semaglutide as an option, check your eligibility with our prescribers, consultations are free, reviewed the same day by a GPhC-registered prescriber, and carry no obligation.